Prevents rejection in renal homotransplantation. ANDA 74419, held by Hikma. Azathioprine Sodium.
As of Nov 16, 2026, ANDA 74419 (Azathioprine Sodium), held by Hikma, was first approved by FDA on Mar 31, 1995, with 7 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Azathioprine Sodium for Injection, USP is indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. Renal Homotransplantation Azathioprine is
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 31, 1995 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Azathioprine SodiumEQ 100MG BASE/VIAL · injectable;injection | Azathioprine Sodium | Rx |
| Jul 9, 2024 | Supplement 18Labeling · Standard review | Approved | None posted |
| Jan 7, 2021 | Supplement 15Labeling · Standard review | Approved | None posted |
| Mar 24, 2014 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 9, 2012 | Supplement 8Labeling | Approved | None posted |
| Jul 27, 2011 | Supplement 6Labeling | Approved | None posted |
| Nov 30, 2000 | Supplement 2Manufacturing | Approved | None posted |
| Aug 18, 1998 | Supplement 1Manufacturing | Approved | None posted |
| Mar 31, 1995 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters